Table 1

Clinical characteristics and renal parameters at baseline

MMF (N=76)TAC (N=74)Total (N=150)
Age, years36.1±13.136.2±1435.5±12.8
Women68 (89)70 (95)138 (92)
SLE duration, months48.2±6352.2±6250.2±62
First time renal biopsy52 (68)50 (68)102 (68)
Concomitant non-renal activity
 Musculoskeletal30 (39)20 (27)50 (33)
 Mucocutaneous29 (38)23 (31)52 (35)
 Haematological23 (30)22 (30)45 (30)
 Neuropsychiatric2 (2.6)1 (1.4)3 (2)
 Serositis11 (14)8 (11)19 (13)
Anti-Ro46 (61)48 (65)94 (63)
Anti-La14 (18)17 (23)31 (21)
Anti-nRNP22 (29)27 (36)49 (33)
Anti-Sm18 (24)14 (19)32 (21)
Anticardiolipin or lupus anticoagulant18 (24)24 (32)42 (28)
Body weight, kg56.3±9.956.7±9.156.5±9.5
Haemoglobin, g/dL10.7±1.910.2±1.810.5±1.9
Serum albumin, g/L26.7±5.628.0±4.527.3±5.1
Serum creatinine, µmol/L83.5±3381.1±3082.3±31
Serum creatinine, mg/dL0.94±0.370.92±0.340.93±0.35
Daily proteinuria, g3.83±3.63.32±2.53.58±3.1
Urine P/Cr ratio4.23±4.13.52±2.53.88±3.4
CrCl (measured), mL/min77.4±2980.5±3379.0±31
Serum C3 level, g/L0.49±0.210.50±0.250.50±0.23
Anti-dsDNA titre, IU/L193±104226±104209±105
CrCl <90 mL/min53 (70)47 (64)100 (67)
Nephrotic syndrome33 (43)31 (42)64 (43)
Hypertension requiring treatment23 (30)36 (49)59 (39)
Active urinary cellular casts31 (41)31 (42)62 (41)
Urine RBC >5 HPF54 (71)58 (78)112 (75)
Use of statin39 (51)36 (49)75 (50)
Use of ACE inhibitor54 (71)56 (76)110 (73)
Use of hydroxychloroquine40 (53)37 (50)77 (51)
Histological classes (ISN/RPS)
 IVG±V26 (34)23 (31)49 (33)
 IVS±V7 (9)12 (16)19 (13)
 III±V31 (41)23 (31)54 (36)
 Pure V12 (16)16 (22)28 (19)
Activity score7.8±3.58.8±3.28.2±3.4
Chronicity score2.6±1.62.6±1.62.6±1.6
  • Values represent mean±SD or number (%).

  • CrCl, creatinine clearance; HPF, high power field; IU, international unit; ISN/RPS, International Society of Nephrology/Renal Pathology Society; MMF, mycophenolate mofetil; P/Cr, protein to creatinine; RBC, red blood cell; SLE, systemic lupus erythematosus; TAC, tacrolimus.